ボルテゾミブの世界市場：製品タイプ別、用途別、エンドユーザー別、地域別

世界のボルテゾミブの市場規模は、2024年に2,454万米ドルと推定され、2024年～2031年にCAGR4.4%を示し、2031年には3,315万米ドルに達すると予測されます。

図.ボルテゾミブ市場シェア（%）、2024年地域別

ボルテゾミブは、一般にベルケイドとして知られるプロテアソーム阻害剤で、標的がん治療薬として作用します。ボルテゾミブは、多発性骨髄腫やその他のがんに対する有効な治療選択肢であることが証明されています。骨髄腫に罹患しやすい高齢者人口の増加とともに、世界のがんの有病率の増加がボルテゾミブの需要を押し上げる可能性があります。ボルテゾミブは希少疾病用医薬品に指定されているため、メーカー各社は同市場への投資を積極化させています。しかし、薬剤の特許失効が市場成長の妨げになる可能性があります。ボルテゾミブの有望な治療効果と用途の拡大は、近い将来、世界のボルテゾミブ市場の成長に有利な機会をもたらす可能性があります。

市場力学：

世界のボルテゾミブ市場の成長は、世界のがん負担の増加によってもたらされています。市場の成長は、多発性骨髄腫の罹患率の増加、症状の追加承認、骨髄腫を発症しやすい高齢者人口の拡大などに起因しています。米国国立がん研究所によると、米国では2020年に15万例以上の多発性骨髄腫が報告されています。また、ボルテゾミブに関連する高額な治療費と研究開発費が市場成長の妨げとなる可能性があります。2015年～2020年にかけて革新的医薬品の特許が失効するため、ジェネリック医薬品の製造が促進され、先発品ベルケイドの売上に悪影響を及ぼす可能性があります。しかし、他の疾患症状におけるボルテゾミブの可能性を評価する試験が進行中であるため、新たな機会がもたらされる可能性があります。

本調査の主な特徴

本レポートでは、世界のボルテゾミブ市場を詳細に分析し、2023年を基準年とした予測期間（2024～2031年）の市場規模および複合年間成長率（CAGR%）を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

世界のボルテゾミブ市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。

本調査の対象となる主要企業は、ジョンソン・エンド・ジョンソン、武田薬品工業、Fresenius SE &Co.KGaA、Dr. Reddy's Laboratories Ltd、Scion Pharma LLCなどです。

本レポートから得られる洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップグレード、市場拡大、マーケティング戦術に関して、十分な情報に基づいた意思決定を行うことができます。

ボルテゾミブの世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。

利害関係者は、世界のボルテゾミブ市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• ポーターの分析
• 合併と買収のシナリオ

第4章 世界のボルテゾミブ市場：製品タイプ別（2019年～2031年）

• 注射
• 注射用粉末

第5章 世界のボルテゾミブ市場：用途別（2019年～2031年）

• 多発性骨髄腫
• マントル細胞リンパ腫
• その他の血液悪性腫瘍

第6章 世界のボルテゾミブ市場：エンドユーザー別（2019年～2031年）

• 病院
• 腫瘍科クリニック
• 外来手術センター
• その他（研究機関、がんセンター）

第7章 世界のボルテゾミブ市場：地域別（2019年～2031年）

• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東

第8章 競合情勢

• Hikma Pharmaceuticals
• Pfizer
• Meitheal Pharmaceuticals
• Novartis International AG
• Bristol Myers Squibb
• NATCO Pharma
• Teva Pharmaceuticals
• Reddy's Laboratories
• Gland Pharma
• Shilpa Medicare
• Qilu Pharmaceutical
• Scion Pharmaceuticals
• Farmhispania Group
• Coresyn
• Chem-Stone（Guangzhou）
• Hubei Honch Pharmaceutical
• Vinkem Labs
• Icrom
• TAPI Teva
• Chengdu Aslee Biopharmaceuticals

第9章 アナリストの推奨事項

• Wheel of Fortune
• アナリストの見解
• Coherent Opportunity Map（COM）

第10章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global bortezomib market is estimated to be valued at USD 24.54 Mn in 2024 and is expected to reach USD 33.15 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

Figure. Bortezomib Market Share (%), By Region 2024

Bortezomib, commonly known as Velcade, is a proteasome inhibitor that acts as a targeted cancer therapy. It has proven to be an effective treatment option for multiple myeloma and other cancers. Increasing prevalence of cancer worldwide along with growing geriatric population susceptible to myeloma can boost demand for Bortezomib. Drug being designated with orphan drug status has encouraged manufacturers to invest in this market. However, patent expiry of the drug can hamper the market growth. Promising therapeutic efficacy and expanding applications of Bortezomib can offer lucrative opportunities for the global bortezomib market growth in the near future.

Market Dynamics:

Global bortezomib market growth is driven by rising cancer burden globally. The market growth can be attributed to increasing incidence rates of multiple myeloma, approval for additional indications, and expanding geriatric population base who are more prone to developing myeloma. As per the National Cancer Institute, more than 150,000 cases of multiple myeloma were reported in the US in 2020. High treatment and R&D costs associated with Bortezomib can hamper the market growth. Patent expiry of innovative drug between 2015 to 2020 has encouraged production of generic versions, and this can negatively impact the sales of branded Velcade. However, ongoing trials evaluating the potential of Bortezomib in other disease indications can present new opportunities.

Key features of the study:

This report provides in-depth analysis of the global bortezomib market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global bortezomib market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Johnson & Johnson, Takeda Pharmaceutical Company Ltd, Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Ltd, and Scion Pharma LLC

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global bortezomib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bortezomib market

Detailed Segmentation-

• By Product Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Injection
  • Powder for Injection
• By Application Insights (Revenue, USD Mn, 2019 - 2031)
  • Multiple Myeloma
  • Mantle Cell Lymphoma
  • Other Hematological Malignancies
• By End User Insights (Revenue, USD Mn, 2019 - 2031)
  • Hospitals
  • Oncology Clinics
  • Ambulatory Surgical Centers
  • Others (Research Institutes, Cancer Centers)
• By Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Hikma Pharmaceuticals
  • Pfizer
  • Meitheal Pharmaceuticals
  • Novartis International AG
  • Bristol Myers Squibb
  • NATCO Pharma
  • Teva Pharmaceuticals
  • Reddy's Laboratories
  • Gland Pharma
  • Shilpa Medicare
  • Qilu Pharmaceutical
  • Scion Pharmaceuticals
  • Farmhispania Group
  • Coresyn
  • Chem-Stone (Guangzhou)
  • Hubei Honch Pharmaceutical
  • Vinkem Labs
  • Icrom
  • TAPI Teva
  • Chengdu Aslee Biopharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Bortezomib Market, By Product Type
  • Global Bortezomib Market, By Application
  • Global Bortezomib Market, By End User
  • Global Bortezomib Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Bortezomib Market, By Product Type, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Injection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Powder for Injection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Bortezomib Market, By Application, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Multiple Myeloma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Mantle Cell Lymphoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Other Hematological Malignancies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Bortezomib Market, By End User, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Oncology Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others (Research Institutes, Cancer Centers)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Bortezomib Market, By Region, 2019 - 2031, (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 220 - 2031, (USD Mn)
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Hikma Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Meitheal Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• NATCO Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Reddy's Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gland Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Shilpa Medicare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Qilu Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Scion Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Farmhispania Group
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Coresyn
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Chem-Stone (Guangzhou)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hubei Honch Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vinkem Labs
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Icrom
• TAPI Teva
• Chengdu Aslee Biopharmaceuticals

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us